JESÚS FERNANDO
SAN MIGUEL IZQUIERDO
Investigador en el periodo 1986-2013
Clínica Universitaria de Navarra
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (18)
2021
2020
-
First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 26, Núm. 10, pp. 2308-2317
2019
-
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
The Lancet, Vol. 394, Núm. 10214, pp. 2096-2107
-
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
Blood, Vol. 134, Núm. 8, pp. 668-677
2017
-
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: A PETHEMA/GEM trial
Leukemia, Vol. 31, Núm. 9, pp. 1922-1927
-
Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bor tezomib and dexamethasone
Haematologica, Vol. 102, Núm. 1, pp. 168-175
2016
-
Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma
American Journal of Pathology, Vol. 186, Núm. 8, pp. 2171-2182
2015
-
Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma
Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, Vol. 1849, Núm. 3, pp. 353-366
-
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations
Leukemia Research Reports, Vol. 4, Núm. 2, pp. 64-69
2013
-
Can CRd be a standard for refractory myeloma?
Blood, Vol. 122, Núm. 18, pp. 3092-3093
2010
-
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma
Clinical Cancer Research, Vol. 16, Núm. 12, pp. 3260-3269
-
Utilización de bisfosfonatos en pacientes con mieloma múltiple: recomendaciones del comité de expertos del Grupo Español de Mieloma del Programa Español de Tratamientos en Hematología
Medicina Clinica, Vol. 134, Núm. 6, pp. 268-278
2008
-
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression
Haematologica, Vol. 93, Núm. 4, pp. 560-565
2006
-
Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma
Hematological Oncology, Vol. 24, Núm. 4, pp. 205-211
2003
-
High-dose therapy in diffuse large cell lymphoma: Results and prognostic factors in 452 patients from the GEL-TAMO Spanish cooperative group
Annals of Oncology, Vol. 14, Núm. 1, pp. 140-151
1998
-
Autologous peripheral blood stem cell transplantation for multiple myeloma: A report of 259 cases from the Spanish Registry
Bone Marrow Transplantation, Vol. 21, Núm. 2, pp. 133-140
1997
-
BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors
Bone Marrow Transplantation, Vol. 20, Núm. 6, pp. 451-458
-
Trasplante autólogo con esquema BEAM en linfoma
Sangre, Vol. 42, Núm. SUPPL. 1, pp. 46-49